bausch,

VAUGHAN, ON and HEIDELBERG, Germany, July 7, 2022 — Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better …

Five Presentations Will Highlight Findings from the XIPERE® Pivotal Phase 3 Program VAUGHAN, ON, July 6, 2022 — Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global …

VAUGHAN, ON, June 23, 2022 — Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “Company”), a leading global eye health company dedicated to helping people see better …

“Using our proprietary technologies for spherical, multifocal, toric and multifocal toric lenses, Revive™ custom soft lenses will allow eye care professionals to use one customizable soft contact lens for a …

First-Quarter 2022 Financial Results Revenues of $889 Million GAAP Net Income of $20 Million Adjusted EBITDA (non-GAAP)1 of $170 Million Bausch + Lomb Commenced Trading Under “BLCO” Ticker Reported Revenues Grew …

Seven Presentations Will Include Unique Research on the New Biotrue® Hydration Plus Multi-Purpose Solution and Biotrue® Hydration Boost Lubricant Eye Drops Company to Also Host Several Sponsored Education Events VAUGHAN, …

“Building on our successful Biotrue® Multi-Purpose Solution brand, we developed Biotrue® Hydration Plus to meet the needs of patients who depend on their contact lenses for the majority of the day …

Campaign Includes Educational Social Media Posts to Broaden Patient Awareness of Cataract Surgery and Care During Cataract Awareness Month VAUGHAN, ON, June 2, 2022 — Bausch + Lomb Corporation (NYSE/TSX: …

VAUGHAN, ON, May 13, 2022 — Bausch + Lomb Corporation, (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better, …

LAVAL, QC and VAUGHAN, ON, May 10, 2022 — Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”) and Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health”) today announced the …

Bausch + Lomb Begins Trading under “BLCO” on NYSE and TSX Fully Integrated Eye Health Business Sets Its Sights On Helping the World See Better To Live Better VAUGHAN, ON, …

By Niket Nishant (Reuters) -Bausch + Lomb was valued at $6.48 billion in its U.S. market debut on Friday as the eye-care company’s shares opened nearly 3% above an offer …

LAVAL, QC and VAUGHAN, ON, May 5, 2022 — Bausch + Lomb Corporation (“Bausch + Lomb”), a wholly owned subsidiary of Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health”), today …

NOV03 Met Primary Endpoints for Signs and Symptoms of Dry Eye Disease Associated with Meibomian Gland Dysfunction in Both Phase 3 Trials VAUGHAN, ON and LAVAL, QC and HEIDELBERG, Germany, …

13 Poster Presentations Include Results from Second Pivotal Phase 3 Trial of Investigational Treatment NOV03 (Perfluorohexyloctane), as well as Data on XIPERE® (Triamcinolone Acetonide Injectable Suspension) for Suprachoroidal Use VAUGHAN, …

LAVAL, QC and VAUGHAN, ON, April 28, 2022 — Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health” or the “Company”) announced today that, in connection with its previously announced intention …

LAVAL, QC and VAUGHAN, ON, April 28, 2022 — Bausch + Lomb Corporation (“Bausch + Lomb”), a wholly owned subsidiary of Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health”), today …

NOV03 Met Both Primary Endpoints for Signs and Symptoms of Dry Eye Disease VAUGHAN, ON and LAVAL, QC and HEIDELBERG, Germany, April 25, 2022 — Bausch + Lomb, a leading …

VAUGHAN, ON and LAVAL, QC and TRENTON, N.J., April 21, 2022 — Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health”), today …

The Term Loan Facility is expected to mature in 2027. The Revolving Credit Facility is expected to mature in 2027 and to be undrawn at closing of the proposed initial …

“Bausch + Lomb is committed to supporting continuous scientific exchange designed to help surgeons get the most out of our current technologies and better understand the potential of those in …

“XIPERE® is the first and only therapy available in the United States that utilizes the suprachoroidal space to treat patients who struggle with macular edema associated with uveitis, which is …